Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05660369 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CARv3-TEAM-E T Cells in Glioblastoma

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 14, 2026 (before its estimated September 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv7
  2. Primary completion date: Jun 1, 2026 to Sep 1, 2026 Completion date: Jun 1, 2027 to Sep 1, 2027 · Eligibility criteria expanded, about 94 words · Study description shortened, about 5 wordsv6 Show 3 more changesShow less
    • Completion date: Jun 1, 2027 to Sep 1, 2027
    • Eligibility criteria expanded, about 94 words
    • Study description shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Jan 1, 2026 to Jun 1, 2026 Completion date: Jan 1, 2027 to Jun 1, 2027v5 Show 1 more changeShow less
    • Completion date: Jan 1, 2027 to Jun 1, 2027
  4. Primary completion date: Jun 1, 2025 to Jan 1, 2026 Completion date: Jun 1, 2026 to Jan 1, 2027v4 Show 1 more changeShow less
    • Completion date: Jun 1, 2026 to Jan 1, 2027
  5. Site contact updatedv3
  6. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Jan 1, 2024 to Jun 1, 2025 · Completion date: Jun 1, 2025 to Jun 1, 2026 · Start date changed from estimate of Jun 2023 to Mar 22, 2023 · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Jan 1, 2024 to Jun 1, 2025
    • Completion date: Jun 1, 2025 to Jun 1, 2026
    • Start date changed from estimate of Jun 2023 to Mar 22, 2023
    • Site details revised
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).
Trial Details
NCT Number NCT05660369
Lead Sponsor Marcela V. Maus, M.D.,Ph.D.
Conditions Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov